Roche-Moscow AO (Russia)

Roche-Moscow AO is a pharmaceutical company located in Moscow. The company is a leader in personalized medicine, thanks to its combination of pharmaceutical and diagnostic divisions. Two-thirds of their R&D projects are developed with the use of accompanying diagnostics. Their portfolio includes 17 biopharmaceutical drugs, with over half of the compounds developed using biotechnology. Roche-Moscow AO has been at the forefront of research and treatment of oncological diseases for over 50 years, offering drugs for the treatment of breast cancer, skin cancer, colorectal cancer, ovarian cancer, lung cancer, and other malignant neoplasms. Their diagnostic solutions help hospitals and laboratories provide doctors with comprehensive information quickly and reliably, enabling effective therapy and meeting patient needs. The company invests approximately 11 billion Swiss francs annually in research and development, making it one of the largest R&D spenders in the healthcare and other sectors worldwide. With a team of over 90,000 employees working in more than 100 countries, Roche-Moscow AO is considered an attractive employer by its employees and external rating agencies. The company has maintained its leadership position in the pharmaceutical, biotechnology, and biomedical sciences fields for many years, as evidenced by its sustainability in the Dow Jones Index.